{"id":56177,"date":"2026-02-03T21:48:18","date_gmt":"2026-02-03T13:48:18","guid":{"rendered":"https:\/\/flcube.com\/?p=56177"},"modified":"2026-02-03T21:48:20","modified_gmt":"2026-02-03T13:48:20","slug":"venglustat-gaucher-sanofi-meets-primary-endpoint-in-phase-3-leap2mono-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56177","title":{"rendered":"Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study"},"content":{"rendered":"\n

Sanofi<\/strong> (NASDAQ:\u202fSNY<\/a>) announced positive results from the LEAP2MONO phase\u202f3 study<\/strong> (NCT05222906), showing venglustat<\/strong> met the primary endpoint<\/strong> and three of four key secondary endpoints<\/strong> in adults and pediatric patients (12\u202fyears and older) with type\u202f3 Gaucher disease (GD3)<\/strong>.<\/p>\n\n\n\n

Clinical Trial Results & Drug Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sanofi (NASDAQ:\u202fSNY)<\/td><\/tr>
Drug<\/strong><\/td>Venglustat (investigational glucosylceramide synthase inhibitor)<\/td><\/tr>
Mechanism<\/strong><\/td>Reduces abnormal accumulation of sugar\u2011and\u2011fat molecules; crosses blood\u2011brain barrier<\/td><\/tr>
Study<\/strong><\/td>LEAP2MONO phase\u202f3 (NCT05222906)<\/td><\/tr>
Patient Population<\/strong><\/td>Adults and pediatrics (\u226512\u202fyears) with neurological manifestations of GD3<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Met<\/td><\/tr>
Secondary Endpoints<\/strong><\/td>3 out of 4 met<\/td><\/tr>
Neurological Outcomes<\/strong><\/td>Statistically significant improvements in SARA modified total score and RBANS at week\u202f52 vs. ERT (p=0.007)<\/td><\/tr>
Non\u2011Neurological Outcomes<\/strong><\/td>Performed as well as ERT on spleen volume, liver volume, and hemoglobin levels<\/td><\/tr>
Safety Profile<\/strong><\/td>Well tolerated, no new safety signals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Strategic Outlook<\/h2>\n\n\n\n